Analysts Set Expectations for QNCX FY2024 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Analysts at Brookline Capital Management issued their FY2024 earnings estimates for Quince Therapeutics in a research report issued to clients and investors on Wednesday, December 18th. Brookline Capital Management analyst K. Raja expects that the company will earn ($1.21) per share for the year. Brookline Capital Management has a “Buy” rating and a $9.00 price objective on the stock. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.14) EPS and FY2028 earnings at $0.52 EPS.

Other analysts have also issued reports about the company. Maxim Group assumed coverage on Quince Therapeutics in a report on Thursday, November 7th. They set a “buy” rating and a $6.00 price objective for the company. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Quince Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Trading Up 1.1 %

NASDAQ:QNCX opened at $1.78 on Friday. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a market cap of $78.32 million, a PE ratio of -1.44 and a beta of 0.74. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a 50-day moving average of $1.61 and a 200-day moving average of $1.03.

Institutional Investors Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC increased its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.